Compare AUPH & ERII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUPH | ERII |
|---|---|---|
| Founded | 1993 | 1992 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 400.7M |
| IPO Year | 2014 | 2008 |
| Metric | AUPH | ERII |
|---|---|---|
| Price | $16.53 | $6.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $17.25 | $17.07 |
| AVG Volume (30 Days) | 741.3K | ★ 933.6K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5075.00 | 5.00 |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $283,055,000.00 | $134,987,000.00 |
| Revenue This Year | $17.54 | N/A |
| Revenue Next Year | $15.74 | $20.55 |
| P/E Ratio | $31.31 | ★ N/A |
| Revenue Growth | ★ 20.38 | N/A |
| 52 Week Low | $10.34 | $6.69 |
| 52 Week High | $19.25 | $18.31 |
| Indicator | AUPH | ERII |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 33.70 |
| Support Level | $15.65 | N/A |
| Resistance Level | $17.02 | $11.58 |
| Average True Range (ATR) | 0.43 | 0.23 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 51.53 | 15.45 |
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Energy Recovery Inc designs and manufactures energy-saving technologies. The firm uses its proprietary pressure exchanger technology to help customers in multiple industries improve their operations and lower their emissions. Using its proprietary technology, it offers energy recovery devices, including pressure exchangers, pumps, and turbochargers, mainly used for seawater desalination and wastewater treatment. Additionally, the company is involved in the development of emerging technologies, such as the PX G1300 used in industrial and commercial refrigeration applications. The firm's reportable operating segments are: Water, which generates maximum revenue, and Emerging Technologies. Geographically, it generates maximum revenue from the Middle East, and the rest from other markets.